Clovis Oncology Net Income 2010-2021 | CLVS

Clovis Oncology net income from 2010 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Clovis Oncology Annual Net Income
(Millions of US $)
2020 $-369
2019 $-400
2018 $-368
2017 $-346
2016 $-349
2015 $-353
2014 $-160
2013 $-85
2012 $-74
2011 $-56
2010 $-38
2009 $-17
Clovis Oncology Quarterly Net Income
(Millions of US $)
2021-09-30 $-67
2021-06-30 $-66
2021-03-31 $-66
2020-12-31 $-99
2020-09-30 $-79
2020-06-30 $-92
2020-03-31 $-99
2019-12-31 $-100
2019-09-30 $-94
2019-06-30 $-120
2019-03-31 $-86
2018-12-31 $-99
2018-09-30 $-90
2018-06-30 $-101
2018-03-31 $-78
2017-12-31 $-52
2017-09-30 $-61
2017-06-30 $-175
2017-03-31 $-58
2016-12-31 $-71
2016-09-30 $-66
2016-06-30 $-129
2016-03-31 $-83
2015-12-31 $-120
2015-09-30 $-99
2015-06-30 $-72
2015-03-31 $-63
2014-12-31 $-55
2014-09-30 $-40
2014-06-30 $-35
2014-03-31 $-31
2013-12-31 $-29
2013-09-30 $-20
2013-06-30 $-19
2013-03-31 $-16
2012-12-31 $-21
2012-09-30 $-18
2012-06-30 $-16
2012-03-31 $-19
2011-12-31 $-15
2011-09-30 $-14
2011-06-30 $-18
2011-03-31 $-8
2010-12-31
2009-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.285B $0.165B
Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.036B 8.91
Bio-Rad Laboratories (BIO.B) United States $17.472B 35.46
QIAGEN (QGEN) Netherlands $11.101B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.210B 0.00
Emergent Biosolutions (EBS) United States $2.527B 9.09
Arcus Biosciences (RCUS) United States $2.184B 0.00
Myovant Sciences (MYOV) United Kingdom $1.260B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.080B 0.00
Zymeworks (ZYME) Canada $0.522B 0.00
SQZ Biotechnologies (SQZ) United States $0.201B 0.00
Ambrx Biopharma (AMAM) United States $0.191B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81